Cochlear Limited reported a 2% increase in constant currency sales revenue for FY26, achieving $2.3 billion, alongside an underlying net profit of $322 million, aligning with revised guidance. The company advanced strategic priorities, including the launch of the Nucleus® Nexa System and increased R&D investment. While developed market revenue rose by 1%, emerging markets faced a 2% decline. Services revenue saw a 6% increase, primarily driven by developed markets. Operating expenses rose by 5%, with notable R&D investments. Looking forward, Cochlear aims to expand access in emerging markets and anticipates modest revenue growth in FY27, targeting a net profit of $330-350 million.
Key Points
Cochlear Limited achieved a 2% increase in constant currency sales revenue for FY26, reaching $2.3 billion.
The company reported an underlying net profit of $322 million, meeting the upper end of revised guidance.
Strategic priorities include the launch of the Cochlear Nucleus® Nexa System and increased investment in R&D.
FY26 saw a sales revenue growth of 6% in the second half, with a significant uptake of the Nucleus Nexa platform.
Developed market revenue increased by 1% in constant currency, while emerging markets saw a decline of 2%.
Services revenue grew by 6% in constant currency, with developed markets showing a 13% increase.
The operating expenditure increased by 5% year-on-year, with a significant investment of 14% of sales revenue in R&D.
Cochlear is focusing on strengthening referral pathways and expanding access to hearing solutions in emerging markets.
The company aims to maintain high standards of product quality, safety, and sustainability in its supply chain.
Cochlear expects low single-digit sales revenue growth and a net profit between $330-350 million in FY27.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.